Mesoblast (MEOBF) 6-K details ASX securities and director interest updates

Rhea-AI Filing Summary

Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information also lodged on the Australian Securities Exchange.

On January 6, 2026, the company filed in Australia a new issue announcement and notification of cessation of securities (Appendix 3H) and a new issue announcement and change of director’s interest notice (Appendix 3Y). These ASX documents are attached to the Form 6-K as Exhibits 99.1 and 99.2 and are incorporated by reference.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On January 6, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of cessation of securities (Appendix 3H) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On January 6, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: January 7, 2026

INDEX TO EXHIBITS

Item
99.1						Appendix 3H of Mesoblast Ltd, dated January 7, 2026.
99.2						Appendix 3Y of Mesoblast Ltd, dated January 7, 2026.

FAQ

What does Mesoblast Limited (MEOBF) report in this Form 6-K?

The Form 6-K from Mesoblast Limited reports that the company has furnished to U.S. investors two announcements it filed with the Australian Securities Exchange on January 6, 2026, relating to securities changes and a director’s interest change.

What is Exhibit 99.1 in Mesoblast (MEOBF) January 2026 Form 6-K?

Exhibit 99.1 is an ASX Appendix 3H new issue announcement and notification of cessation of securities of Mesoblast Ltd, dated January 7, 2026, which is incorporated into the Form 6-K by reference.

What is Exhibit 99.2 in Mesoblast (MEOBF) January 2026 Form 6-K?

Exhibit 99.2 is an ASX Appendix 3Y new issue announcement and change of director’s interest notice of Mesoblast Ltd, dated January 7, 2026, and is also incorporated into the Form 6-K by reference.

Why does Mesoblast (MEOBF) file ASX Appendices 3H and 3Y with the SEC?

As a foreign private issuer, Mesoblast files Form 6-K to make material information released in its home market, such as ASX Appendices 3H and 3Y on securities and director interest changes, available to U.S. investors.

Who signed Mesoblast Limited’s January 2026 Form 6-K?

The Form 6-K was signed on behalf of Mesoblast Limited by Company Secretary Niva Sivakumar, dated January 7, 2026.